

COMPANY REGISTRATION NUMBER: 07264864

PELICAN CANCER FOUNDATION


FINANCIAL STATEMENTS

FOR THE YEAR ENDED

31 MARCH 2018

CHARITY NUMBER 1141911

FRIDAY



A7L9ASK0

A15

21/12/2018

#331

COMPANIES HOUSE

taylorcocks

3 Acorn Business Centre
Northarbour Road
Cosham
Portsmouth
PO6 3TH

PELICAN CANCER FOUNDATION

CHARITY INFORMATION

FOR THE YEAR ENDED 31 MARCH 2018

Trustees	Sir P Michael CBE (Chairman) Professor R Heald CBE Mr B Moran Mr M Rees Mr G C S Mather CBE Mr J Wood Mr R King Mrs S Arnold Mr F Mohamed Ms D Fielding Mr W Boyd Mr H Gardener Mrs M Batstone	<i>resigned 18 July 2018</i> <i>resigned 17 July 2018</i> <i>appointed 11 April 2017</i> <i>resigned 31 March 2018</i> <i>appointed 8 May 2018</i> <i>appointed 17 July 2018</i>
Charity registration number	1141911	
Company number	07264864	
Charity address	The Pelican Cancer Foundation The Ark Dinwoodie Drive Basingstoke Hampshire RG24 9NN	
Auditors	taylorcocks 3 Acorn Business Centre Northharbour Road Cosham Portsmouth PO6 3TH	
Bankers	CAF Bank 25 Kings Hill Avenue Kings Hill West Malling Kent Barclays Bank Plc Market Place Basingstoke Hampshire	

PELICAN CANCER FOUNDATION

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2018

CONTENTS	PAGE
Trustees' report	1 - 7
Auditors' report	8 - 11
Statement of financial activities	12
Balance sheet	13
Notes to the financial statements	14 - 24

PELICAN CANCER FOUNDATION

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

Welcome to the 2017 - 2018 annual report and financial statements.

The Trustees are pleased to present their report with the audited financial statements of the Charity for the year ended 31 March 2018.

The financial statements comply with the statutory requirements, the Trust Deed and the Statement of Recommended Practice - Accounting and Reporting by Charities (FRS 102) issued on 16 July 2014.

INTRODUCTION

Established in 1993, as the Basingstoke Bowel Cancer Project, the Charity became The Pelican Cancer Foundation in 2000. Pelican was formed to advance greater understanding and treatment of bowel cancer.

Pelican is about helping today's bowel and urology cancer patients live better for longer through research and education initiatives to advance precision treatment.

CHIEF EXECUTIVE'S STATEMENT

In this reporting period 2017 - 2018 there have been exciting developments in all our areas of work from the treatment of early bowel cancer, diagnosis of prostate cancer and treatment for advanced (metastatic) bowel cancer.

Medical knowledge is always shared to encourage greater understanding and we are deeply indebted to the many doctors and nurses who gave their time to advise, guide and deliver our training programmes and oversee our research.

Nothing would be possible without the generous and committed help of our wonderful supporters who donated to the charity, ran events and joined committees.

Sarah Crane
August 2018

HIGHLIGHTS OF 2017 - 2018

SPECC | Significant Polyp & Early Colorectal Cancer National Development Programme completed in December 2017. Thanks to an exceptional 'faculty' of experts this programme has run 15 workshops in England, Ireland, Scotland and Wales for 1,337 clinicians from 173 hospitals. Over 100 specialists were involved with giving talks and presenting case studies. For the first time we ran workshops in Scotland and Ireland, both working to different systems but receptive and grateful for this expert led initiative.

In January 2018 we started the follow up Pelican IMPACT – Improving the Management for Patients with Advanced Colorectal Tumours. A national programme, similar in scope to SPECC, delivered in partnership with the Association of Coloproctology of Great Britain and Ireland.

Quotes from consultants attending workshops:

'One of the best courses I have attended throughout my career. Thank you'

'Excellent organisation, highly esteemed speakers and great focus on patient perspective/care'

The Pelican research fellow, Mr Nick Battersby, won the Robert W. Beart, MD, Impact Paper of the Year Award by the journal for the American Society of Colon and Rectal Surgeons for his paper on quality of life after rectal surgery - part of the LARS study that Pelican supported.

A wonderful new website was launched in the autumn thanks to the generosity of Artificial Labs who ran a competition with Just Giving, which Pelican won in 2015.

PELICAN CANCER FOUNDATION

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Charity incorporated in 2012 and the new Charity number is 1141911 (England and Wales) and the company number is 7264864 (England).

The Trustee board, who are also directors of the company, provide the strategic direction for the Charity with authority delegated to the Chief Executive Officer, Mrs. Sarah Crane, for the overall management and administration of the Charity.

The Board appoints Trustees when necessary to meet the changing demands of the Charity. Appropriate induction briefings and training are available for newly appointed trustees.

The full Board of Trustees meets at least twice a year;

In spring - to confirm the strategic aim and agree budget projection/allocation for the coming financial year, review risk.

In autumn - to accept audited accounts, annual report, risk assessment, to monitor in year activity and recommendations from the Research Review Panel.

The Trustee Board may meet at other times as necessary and the Chief Executive regularly meets with the Chairman of Trustees and individual Trustees.

The Charity has a scientific advisory board known as the Pelican Research Review Panel (PRRP) which helps direct the research activity, review all research applications and maintain oversight of existing research.

Trustees

Sir Peter Michael CBE	Chairman
Professor R Heald CBE	Professor of Surgery
Mr B Moran	Colorectal Surgeon
Mr M Rees	Hepatobiliary Surgeon and Clinical Director of Surgery
Mr G C S Mather	Lawyer
Mr J Wood	Retired Businessman
Mr R King	Businessman
Mrs S Arnold	Colorectal Surgeon
Mr F Mohamed	Colorectal Surgeon
Ms D Fielding	Director Marketing
Mr W Boyd - <i>appointed 11 April 2017</i>	Author
Mrs M Batstone	Ex-NHS Chief Executive

Pelican Research Review Panel

Professor C Shearman	Chairman
Mr G Branagan	Consultant Colorectal Surgeon
Mr A Mirnezami	Consultant Colorectal Surgeon
Dr A Kirkham	Consultant Radiologist
Mr A Belgaumkar	Hepatobiliary Surgeon
Dr N Shah	Consultant Radiologist
Mr F Di Fabio	Consultant Colorectal Surgeon
Mrs S Crane	Pelican Chief Executive

CHARITY FUNDS

The Pelican Reserves Policy 2017 - 2018

The charity's Reserves Committee met several times in this period to discuss moving the charity reserves, which are now managed by Rathbones.

PELICAN CANCER FOUNDATION

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

The Trustees discussed the Reserves Policy and agreed to hold sufficient reserves to allow the Charity and its associated activities to continue for 12 months (£600,000), as per the recommendations of the Charity Commission. In addition, the Charity holds funds to run two national programmes - Pelican IMPACT and the Pelican Prostate Cancer Programme.

The Charity has committed to grants valued at £46,858 currently outstanding, and pledged a further £49,500 as we do not pay grants until projects are underway or research staff have been engaged. A further £100,000 will be advertised for seed funding research in 2018 - 2019.

Risk

A risk assessment is continuously monitored and presented at Trustee meetings.

This year the change in GDPR and privacy laws were identified as the highest risk followed by risks identified related to the uncertainty of future income. An annual budget is developed and approved by the trustees.

Public Benefit

The Trustees confirm that they have complied with their duty in section 17 of the Charities Act 2011 and due regard to the public benefit guidance published by the Commission in determining the activities undertaken by the Charity. The Trustees report sets out how the Charity addresses the public benefit requirement.

AIM, OBJECTIVES AND ACTIVITIES

Charitable Objects

For the public benefit to advance research education and treatment of cancer in particular but not exclusively bowel cancer, other pelvic malignancies, liver cancer and related diseases.

Vision - what do we want to do in 2018 and beyond?

Help cancer patients live for longer with a better quality of life. Help cancer clinicians advance their understanding and treatment of cancer.

Mission - why do we exist/what do we want to achieve?

Help clinicians advance their skills and understanding of precision treatment for bowel, liver and urology cancers. Support research and researchers investigate innovative precision cancer treatments. Disseminate knowledge of innovative research and advances in precision treatment.

Achievements

The long-term achievement of Pelican Cancer Foundation is the radical change in rectal cancer management: the widespread international adoption of Total Mesorectal Excision (TME) as the gold standard surgical treatment for bowel cancer. Added to this is the development of multi-disciplinary treatment: the integration of imaging with MRI as a guide to surgery, individualised adjuvant therapy planning, precise surgery and histopathological analysis has all helped patients to live better for longer. These are all areas that Pelican has pioneered and, through advanced training and development, has helped to embed in NHS practice in England and Wales.

In prostate cancer the charity seed funded the early research into focal therapies for prostate cancer and the use of MRI for more precise early diagnosis. Both of these are having a worldwide influence on the management and treatment of prostate cancer.

PELICAN CANCER FOUNDATION

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

ACHIEVEMENTS AND PERFORMANCE 2017 - 2018

Courses & Education

The Charity is fortunate to have exceptional teaching facilities that are used to host courses and meetings for surgical cancer specialists and their multi-disciplinary teams. The Charity organised 19 conferences and workshops (19 in 2016-2017) throughout the reporting period, with 1,159 delegates attending (945 in 2016-2017) and 230 speakers and faculty. There was a deficit in income for the conference and workshops due to so many being free to attend but we were grateful to those who paid fees, industry sponsorship, education grants and donations.

The SPECC and Pelican IMPACT national development programmes absorbed the majority of the charity's activity: workshops which multidisciplinary bowel cancer teams can attend for free to advance their understanding and practice. At the same time the Charity delivered a curriculum of exciting and challenging multi-disciplinary meetings and courses for bowel, liver and prostate cancer.

Support for Basingstoke & North Hampshire Hospital

Pelican Cancer Foundation offices are located adjacent to Basingstoke & North Hampshire Hospital (part of Hampshire Hospitals NHS Foundation Trust (HHFT)), many of our speakers come from the hospital and surgical filming is streamed from the hospital's operating theatres for courses.

Every person diagnosed with cancer is discussed by a multidisciplinary cancer team. Pelican regularly hosts 11 of these meetings in our purpose built MDT meeting room. The Charity also hosts research meetings, further clinical meetings and video conferences. There are over 4,500 cancer patients discussed every year.

Medical Research Activity

Pelican Cancer Foundation is a member of the Association of Medical Research Charities and a non-commercial Partner Organisation with the National Institute of Health Research. All research is selected and monitored in line with AMRC recommendations and the oversight of the Pelican Research Review Panel (PRRP).

The Charity advertised research funding to over 2,000 cancer specialists in August 2017 and received 11 complete applications. After the full process of grant review and consideration funding was agreed for 2 new projects, a further 2 new studies are still under review. The Pelican Research fellow post was advertised but was gapped from October 2017 – October 2018.

A number of papers were published in high impact professional journals and both the faculty and fellows presented their research at international meetings.

Professor Heald

Professor Heald is an international advocate advancing precision surgery for bowel cancer and travelled widely in this period.

Professional fees

During the financial year Prof Heald received professional fees totalling £15,000 for representing the Charity worldwide, speaking at international conferences and disseminating research findings on behalf of Pelican Cancer Foundation.

Income generation and Fundraising

The Charity was particularly grateful to all those supporters who gave donations to the Charity and attended charitable events as the Charity's research would not be possible without this income.

PELICAN CANCER FOUNDATION

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

Remuneration

As a charity, Pelican relies heavily on donated funds and the ongoing support of volunteers and funders; it is important to us that these resources are used to maximum effect.

In order to run Pelican as an efficient and effective organisation able to deliver quality services, Pelican employs 6 FTE.

Staff costs (salaries and pension contributions) make up a large proportion of the annual cost of running Pelican. Managing staff costs whilst ensuring that the charity has the appropriate mix of skills and expertise to achieve its objectives is an important part of ensuring the ongoing success and viability of the Charity. The total staff costs for Pelican in 2017/2018 was £224,389.

Human Resources

The Charity has a small staff and during the year there were no outstanding HR issues.

FINANCIAL REVIEW

In this previous period the Pelican Reserves Committee (Jonathan Wood, Daryl Fielding and Sarah Crane) met three times and reported to the trustees. It was agreed that the invested reserves would be managed by Rathbones going forward.

PLANS FOR 2018

Pelican Teaching and Meetings

- Provide education and development opportunities for surgeons and multi-disciplinary cancer teams
- Continue to deliver Pelican IMPACT – Improving the Management for Patients with Advanced Colorectal Tumours throughout 2018 - 19
- Initiate the first Prostate Cancer National Programme from January 2019
- Run courses of interest and high standard for clinicians
- Attract high profile and influential faculty and presenters
- Provide expert and professional support for meetings and seminars booked through Pelican
- Market courses widely, effectively and economically
- Raise sufficient funds for this activity to be self-supporting
- Keep accurate records of all activity

Research

- Develop a respected and meaningful research portfolio for advances in precision surgery for pelvic region and metastatic cancers
- Advertise annual grant rounds for studies that advance precision treatment of cancer
- Ensure good governance of the grant giving and studies in the Pelican research portfolio
- Develop training and development where Pelican research projects have led to a change in surgical practice
- Keep accurate records of all research, publications and presentations
- Seek funding opportunities to support the research activity

Raise Awareness of

- The importance of precise cancer treatment, with an emphasis on surgery
- Aspects of the Total Mesorectal Excision concept, which form the core of many current advances in the management of rectal cancer
- Prostate cancer treatment, in particular over diagnosis and over treatment
- The Charity's achievements, new courses and research as appropriate

PELICAN CANCER FOUNDATION

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

Publicity

- Raise the profile of the Charity
- Maintain an informative and relevant website
- Sustain and increase our social media presence
- Produce regular electronic and hard copy newsletters for supporters
- Submit regular hard copy for local and national press

Pelican Administration

- Ensure good human resources policies and practices that support and encourage all those who work for the Pelican team
- Develop good accounting practice that is transparent and open
- Collaborate with other charities to improve outcomes

Fundraising

- Raise sufficient funds to support the above activities
- Adhere to best practice in fundraising policies and activities
- Encourage a broad range of fundraising methods that are cost effective

STATEMENTS OF TRUSTEES' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales/Northern Ireland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the Charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2015 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

PELICAN CANCER FOUNDATION

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

AUDITORS

taylorcocks have expressed their willingness to continue in office and a resolution to reappoint them will be proposed at the annual general meeting.

This report was approved by the Board of Trustees on 20 September 2018

B Moran

A handwritten signature in black ink, appearing to be 'B Moran', written over a horizontal line. The signature is stylized and cursive.

PELICAN CANCER FOUNDATION

AUDITORS' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

We have audited the financial statements of the Pelican Cancer Foundation Charity (the 'charitable company') for the year ended 31 March 2018 which comprise the statement of financial activity, balance sheet and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2018, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

PELICAN CANCER FOUNDATION

AUDITORS' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

Other information

The trustees are responsible for the other information. The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

As explained more fully in the trustees' responsibilities statement set out on page 6, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

PELICAN CANCER FOUNDATION

AUDITORS' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 145 of the Charities Act 2011 and report in accordance with regulations made under section 154 of that Act.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

PELICAN CANCER FOUNDATION

AUDITORS' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



James Blake FCA (Senior Statutory Auditor)

For and on behalf of

taylorcocks

Statutory Auditors

Office: *Portsmouth*

Date: *12 December 2018*

Taylorcocks is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

PELICAN CANCER FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 MARCH 2018

	Notes	Restricted Funds 2018 £	Unrestricted Funds 2018 £	Total Funds 2018 £	Total Funds 2017 £
Incoming Resources					
Incoming resources from generated funds:					
Voluntary income	2	24,609	139,970	164,579	282,575
Investment income	2	-	8,610	8,610	147
Trust income	2	51,363	14,000	65,363	74,750
Legacy income	2	-	62,436	62,436	-
Fundraising income	2	-	24,325	24,325	-
Income resources from charitable activities:					
Courses	2	7,864	42,821	50,685	115,010
Other income:					
Refund re R&D repaid	2/17	-	(28,648)	(28,648)	-
Total incoming resources		83,836	263,514	347,350	472,482
Resources expended					
Cost of generating funds	3	5,444	194,839	200,283	142,794
Charitable activities:					
Research expenditure	3	35,113	75,876	110,989	165,540
Course costs	3	59,712	145,753	205,465	211,411
Total Resources expended		100,269	416,468	516,737	519,745
Unrealised gains / (losses) on revaluation of investment assets					
		-	(19,335)	(19,335)	132,377
Net incoming resources for the year		(16,433)	(172,289)	(188,722)	85,114
Transfer between funds		3,266	(3,266)	-	-
Net movement of funds		(13,167)	(175,555)	(188,722)	85,114
At 31 March 2017		27,616	1,467,348	1,494,964	1,409,850
At 31 March 2018		14,449	1,291,793	1,306,242	1,494,964

All incoming resources and resources expended derive from continuing activities.

The notes on
s 14 to 24 form part of these financial statements.

PELICAN CANCER FOUNDATION


BALANCE SHEET

FOR THE YEAR ENDED 31 MARCH 2018

	Notes	2018		2017	
		£	£	£	£
Fixed assets					
Tangible assets	7		7,893		4,821
Investments	8		1,000,000		1,315,799
Current assets					
Accounts receivable		2,915		15,302	
Prepayments and other debtors		15,650		20,654	
Cash at bank and in hand		618,543		295,390	
		<u>637,108</u>		<u>331,346</u>	
Creditors: amounts falling due within the year					
Accounts payable		32,286		37,053	
Employment creditors		7,270		7,300	
Accruals		5,100		4,800	
Grants pledged	9	46,858		87,833	
Deferred income		247,245		20,016	
		<u>338,759</u>		<u>157,002</u>	
Net current assets			298,349		273,986
Total assets less current liabilities			<u>1,306,242</u>		<u>1,494,964</u>
Funds					
Restricted	10		14,449		27,616
Designated	11		1,117,255		1,117,255
General	11		174,538		350,093
			<u>1,306,242</u>		<u>1,494,964</u>

These financial statements were authorised for issue and approved by the Trustees on 20 September 2018

Professor B Moran



Company registration number: 07264864

The notes on pages 14 to 24 form part of these financial statements.

PELICAN CANCER FOUNDATION
NOTES TO FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018

1. ACCOUNTING POLICIES

Charity information

Pelican Cancer Foundation is a charitable company incorporated in England and Wales. The registered office is The Ark, Dinwoodie Drive, Basingstoke, Hampshire, RG24 9NN.

Accounting conventions

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Charities Act 2011, the Companies Act 2006 and the UK Generally Accepted Accounting Practice.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest pound.

The accounts have been prepared under the historical cost convention. The principal accounting policies adopted in the preparation of the financial statements are set out below.

Going Concern

At the time of approving the accounts, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of the accounting in preparing the accounts.

Incoming Resources

Charitable trading activities

Income from courses, meetings and reimbursed travel is included in incoming resources in the period in which relevant expenditure is incurred.

Grants are credited to income in the year they are received. Specific grants are matched with related expenditure and charged to the periods in which the expenditure is incurred.

Fundraising income

Fundraising income is recognised in the period in which the fundraising event takes place.

Donations and legacies

Income from donations is included in incoming resources when receivable. For legacies, entitlement is the earlier of the charity being notified of an impending distribution or the legacy being received.

Interest receivable

Interest is included when receivable by the charity.

Resources expended

Resources expended are included in the Statement of Financial Activities on an accruals basis, inclusive of any VAT which cannot be recovered.

Certain expenditure is directly attributable to specific activities and has been included in those cost categories. Wages are split on a proportion of time spent on activities. Certain other costs, which are attributable to more than one activity, are apportioned across cost categories on the basis of the proportion of resource allocated to those activities.

PELICAN CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2018

Grants payable to third parties to fund research activities are within the charitable objectives. Where unconditional grants are offered, this is accrued as soon as the recipient is notified of the grant, as this gives rise to reasonable expectation that the recipient will receive the grant. Where grants are conditional relating to performance then the grant is only accrued when any unfulfilled conditions are outside of the control of the charity.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's statement of financial position when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financial transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financial transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations. Amounts payable are classified as current liabilities if payment is due within one year. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Taxation

The charity is considered to pass the tests set out in paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to extent that such income or gains are applied exclusively to charitable purposes.

PELICAN CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2018

Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of the assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may vary from these estimated.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised in the period in which the estimates are revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees have considered whether there are critical judgements required in the preparation of these accounts and have concluded that there are none requiring disclosure.

Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost, being purchase price plus any incidental costs of acquisition, less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

Computers	-	25% straight line
Equipment	-	25% reducing balance

Investments

Investments listed on a recognised stock exchange are stated at mid market value in the balance sheet. All movements in value arising from changes and revaluations are included in the Statement of Financial Activities.

Pension costs

The charity offers employees the opportunity to participate in a group pension scheme. Contributions paid by the charity during the year are disclosed within the accounts in accordance with the applicable accounting standards.

Fund accounting

Funds held by the charity are either

- *Unrestricted general funds* - these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.
- *Designated funds* - these are funds set aside by the trustees out of unrestricted general funds for specific future purposes or projects.
- *Restricted funds* - these are funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each restricted fund is included in the note 10 to the financial statements.

PELICAN CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2018

2. INCOMING RESOURCES

	Restricted funds		Unrestricted funds		Total funds	
	2018	2017	2018	2017	2018	2017
	£	£	£	£	£	£
<u>Income resources from generating funds</u>						
Voluntary Income	24,609	22,137	139,970	260,438	164,579	282,575
Investment Income	-	-	8,610	147	8,610	147
Trust Income	51,363	54,750	14,000	20,000	65,363	74,750
Legacy Income	-	-	62,436	-	62,436	-
Fundraising Income	-	-	24,325	-	24,325	-
<u>Income resources from charitable activities</u>						
Courses	7,864	8,000	42,821	107,010	50,685	115,010
<u>Other Income</u>						
Refund re R&D repaid	-	-	(28,648)	-	(28,648)	-
Total costs	<u>83,836</u>	<u>84,887</u>	<u>263,514</u>	<u>387,595</u>	<u>347,350</u>	<u>472,482</u>

3. RESOURCES EXPENDED

	Cost of generating	Research	Course	Total	Total
	funds	expenditure	costs	2018	2017
	£	£	£	£	£
Training courses	-	-	87,459	87,459	90,357
Research expenditure	-	48,255	-	48,255	106,293
Wages and salaries	93,339	32,684	66,784	192,807	174,707
Facilities costs	8,404	8,404	16,807	33,615	33,128
Consultancy and professional fees	16,615	5,673	11,347	33,635	34,233
Fund raising costs	53,648	-	-	53,648	27,499
Website	1,540	-	1,540	3,080	4,938
Support costs	26,737	15,973	21,528	64,238	48,590
Total costs	<u>200,283</u>	<u>110,989</u>	<u>205,465</u>	<u>516,737</u>	<u>519,745</u>

PELICAN CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2018

3. RESOURCES EXPENDED (continued...)

	2018	2017
	£	£
Analysis of support costs		
Depreciation	2,296	1,560
IT costs	7,032	6,834
Management administration	29,516	20,415
Audit fees	5,100	4,800
Bank fees	2,292	2,765
Other support costs	18,002	12,216
	<u>64,238</u>	<u>48,590</u>

Certain expenditure is directly attributable to specific activities and has been included in those cost categories. Wages are split on a proportion of time spent on activities. Certain other costs, which are attributable to more than one activity, are apportioned across cost categories on the basis of the proportion of resource allocated to those activities.

4. STAFF COSTS AND TRUSTEES' REMUNERATION

	2018	2017
	£	£
Staff costs and trustee's remuneration		
Wages and salaries	174,568	143,385
Social security	12,386	9,380
Pension costs	37,435	39,140
	<u>224,389</u>	<u>191,905</u>

No employee earned more than £60,000 in the year (2017 – no employee earned more than £60,000).

5. STAFF NUMBERS

The average number of employees during the year was made up as follows:

	2018	2017
	No	No
Total	<u>6</u>	<u>5</u>

6. NET INCOMING RESOURCES FOR THE YEAR

This is stated after charging:

	2018	2017
Auditors remuneration – as auditor	5,100	4,800
Depreciation	<u>2,296</u>	<u>1,560</u>

PELICAN CANCER FOUNDATION
NOTES TO FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018

7. TANGIBLE FIXED ASSETS – FOR CHARITIES OWN USE

	Computers £	Equipment £	Total £
Cost			
At 1 April 2017	82,061	24,505	106,566
Additions	5,368	-	5,368
Disposals	-	-	-
At 31 March 2018	<u>87,429</u>	<u>24,505</u>	<u>111,934</u>
Depreciation			
At 1 April 2017	77,408	24,337	101,745
Depreciation charge	2,256	40	2,296
Depreciation on disposals	-	-	-
At 31 March 2018	<u>79,664</u>	<u>24,377</u>	<u>104,041</u>
Net book value			
At 31 March 2018	<u>7,765</u>	<u>128</u>	<u>7,893</u>
At 31 March 2017	<u>4,653</u>	<u>168</u>	<u>4,821</u>

PELICAN CANCER FOUNDATION
NOTES TO FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018

8. INVESTMENTS

	2018	2017
	£	£
Market value		
At 1st April 17	1,315,799	1,063,650
Purchases	977,830	517,579
Proceeds of sales	(1,502,135)	(264,705)
Gain/(loss) on disposal	174,009	22,909
(Loss)/gain on revaluation	(379,573)	(123,276)
Cash held by investment managers	414,070	99,642
At 31 March 2018	<u><u>1,000,000</u></u>	<u><u>1,315,799</u></u>

The charity holds a portfolio of listed investments which it uses to generate income for use in the charity's operations. The trustees regularly monitor the performance of the charity's investments and set the investments strategy. The investment portfolio is managed on a day- to- day basis by a third party investment management company, who enact the trustees' investment strategy.

PELICAN CANCER FOUNDATION
NOTES TO FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018

9. ANALYSIS OF GRANTS

For the year ending 31 March 2018

	Research expenditure £
Grants pledged during the year 2017-18	
Study to identify pre-,peri- or post-operative factors that might contribute to thrombosis and bleeding risks in patients undergoing hepatic resection for colorectal liver metastases	15,000
Concordance between MRI and pathology in the diagnosis of extraadrenal tumour deposits	19,860
Grants released due to expiry of time limits on applications	(35,478)
Pelican Research Fellow expense during the year	24,249
Conference call costs of research panel	44
	23,675
Grants payable charged to the SoFA in the year	23,675
	Grants pledged £
Grants payable at 31 March 2017	87,833
Grants released due to expiry of time limits on applications	(35,478)
Grants paid during the year	(40,357)
Additional grant applications made and approved	34,860
	46,858
Grants payable at 31 March 2018	46,858

In addition to the above, the trustees had also approved the following grants to be made at 31 March 2018, but which are not accrued for within these financial statements, as the charity still had control of these funds at 31 March 2018:

	Grants approved £
A Longitudinal, Prospective, International Analysis of Patient Reported Outcomes in Locally recurrent Rectal Cancer	24,500
PRE-therapeutic MRI assessment of Early Stage Rectal Cancer and significant Rectal Polyps to avoid major resectional surgery: A new approach to the management of Early stage rectal cancer	25,000
	49,500
Grant pledges committed, but not accrued at 31 March 2018	49,500

PELICAN CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2018

10. RESTRICTED FUNDS

At 31 March 2018, there is £14,449 carried forward within Restricted Funds (2017 - £27,616).

	At 1 April 2017 £	Incoming resources £	Outgoing resources £	Transfers £	At 31 March 2018 £
Restricted funds					
SPECC – Training Programme	11,616	15,006	(28,734)	2,112	-
IMPRESS – Research Trial	2,000	-	-	-	2,000
Educational grants	-	17,357	(18,511)	1,154	-
Education grant – Liver	10,000	-	(10,000)	-	-
MDT Room	-	2,132	(2,132)	-	-
FORECAST – Research Trial	2,000	-	-	-	2,000
Parlarc Research	2,000	-	-	-	2,000
Event equipment	-	1,700	-	-	1,700
CPM Database	-	25,000	(25,000)	-	-
Pelican IMPACT	-	22,641	(15,892)	-	6,749
Total Restricted funds - 2018	27,616	83,836	(100,269)	3,266	14,449

At 31 March 2017, there was £27,616 carried forward within Restricted Funds (2016 - £24,520).

	At 1 April 2016 £	Incoming resources £	Outgoing resources £	Transfers £	At 31 March 2017 £
Restricted funds					
TRIGGER – Research Trial	-	14,000	(14,000)	-	-
SPECC – Training Programme	-	21,750	(10,134)	-	11,616
IMPRESS – Research Trial	2,000	-	-	-	2,000
SPECC West Midlands	500	-	(500)	-	-
Educational grants	-	22,137	(12,137)	-	10,000
3D Camera	20,020	-	(23,563)	3,543	-
FORECAST – Research Trial	2,000	-	-	-	2,000
Parlarc Research	-	2,000	-	-	2,000
Pelican Fellow	-	25,000	(25,000)	-	-
Total Restricted funds - 2017	24,520	84,887	(85,334)	3,543	27,616

PELICAN CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2018

11. UNRESTRICTED CHARITY FUNDS 2018

	At 1 April 2017	Incoming resources	Outgoing resources	Transfers	At 31 March 2018
	£	£	£	£	£
Designated funds					
Contingency reserve	600,000	-	-	-	600,000
Research & Education commitments	417,255	-	-	-	417,255
Fixed asset fund	100,000	-	-	-	100,000
Total Designated funds	1,117,255	-	-	-	1,117,255
General funds	350,093	255,155	(427,444)	(3,266)	174,538
Total Unrestricted funds - 2018	1,467,348	255,155	(427,444)	(3,266)	1,291,793
Designated funds					
Contingency reserve	600,000	-	-	-	600,000
Research & Education commitments	500,000	-	(82,745)	-	417,255
Fixed asset fund	100,000	-	-	-	100,000
Total Designated funds	1,200,000	-	(82,745)	-	1,117,255
General funds	185,330	519,972	(351,666)	(3,543)	350,093
Total Unrestricted funds - 2017	1,385,330	519,972	(434,411)	(3,543)	1,467,348

PELICAN CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2018

12. ANALYSIS OF NET ASSETS BETWEEN FUNDS 2018

	Unrestricted funds			Total
	Designated Funds	General Funds	Restricted Funds	
	£	£	£	£
Fixed asset investments	1,000,000	-	-	1,000,000
Tangible fixed assets	7,893	-	-	7,893
Cash at bank and in hand	-	387,345	231,198	618,543
Other net assets/ (liabilities)	109,362	(212,807)	(216,749)	(320,194)
	<u>1,117,255</u>	<u>174,538</u>	<u>14,449</u>	<u>1,306,242</u>

13. FINANCIAL COMMITMENTS

The charity has an agreement with The Ark Conference Centre Limited to pay a proportion of costs for use of the building. The annual costs are estimated at between £35,000 and £40,000.

14. CAPITAL COMMITMENTS

There were no capital commitments, either contracted or authorised by the Trustees, at 31 March 2018.

15. CAPITAL

The company does not have a share capital as it is limited by guarantee. Each of the members is a guarantor to the extent of £1 in the event of the company being wound up whilst they are still members, in respect of debts and liabilities contracted before they ceased to be a member. There were 11 members at 31 March 2018 (2017 – 11 members).

16. RELATED PARTY TRANSACTIONS

During the year the trustees made donations to the charity totalling £1,100 (2017 - £580), and payments for events run by the charity of £1,750 (2017 - £nil).

During the year 2017/18 professional fees were paid to Professor R Heald CBE totalling £15,000 (2017 – £15,000). At the year end the charity owed Professor R Heald CBE £3,750 (2017 - £3,750).

17. REFUND REGARDING RESEARCH AND DEVELOPMENT

During the 2016 financial year, the charity sought third party professional advice and made a claim for a research and development tax credit. This was initially successful and the charity received £28,056 which was reflected in the 2016 financial statements. During the 2018 financial year HM Revenue & Customs reassessed this claim and the charity had to repay the amount received with interest totalling £28,648. The difference between the amount initially received and repaid is due to be paid by third party R&D firm however this has not been received yet and no accrued income has been recognised for this.